Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study involved a Delphi-method consensus from 34 Spanish dermatologists, outlining structured recommendations for managing androgenetic alopecia based on available scientific evidence and expert opinions, aiming to guide clinical practice amid limited treatment approvals and varying effectiveness.

This review discusses medical treatments for hirsutism, focusing on oral contraceptives and other therapies, but reports no new results; the authors emphasize the lack of evidence for insulin sensitizers in treating hirsutism alone.

This review examines the pharmacological properties and potential clinical benefits of 5α‐reductase inhibition in prostate cancer but reports no new research findings.

This review discusses frontal fibrosing alopecia in males and reports no new clinical results, indicating a broader demographic affected by this inflammatory disorder beyond postmenopausal women.

This study assessed the psychosocial impact and disease burden of alopecia areata among adolescents and adults in Australia, finding substantial impacts on physical, emotional, and quality of life overall, with greater disease burden in patients experiencing more extensive hair loss.

Low-dose oral minoxidil effectively treats female hair loss with good safety.

This study found that low-dose tamoxifen may effectively treat painful gynecomastia in patients receiving flutamide and finasteride for advanced prostate cancer.

Scientists made the first metal-based compounds from a nonsteroidal antiandrogen drug, which showed potential in fighting both hormone-dependent and independent prostate cancer cells.

Androgens and SARMs play a role in body mass, frailty, skin health, and hair growth, and are used in treating prostate cancer, acne, and hair loss, with potential for new uses and improved versions in the future.

This study suggests that certain Dibenzo derivatives may be promising candidates for prostate cancer treatment due to their potential interactions with the androgen receptor and 5α-reductase enzyme.

In this prospective phase II clinical trial, researchers are investigating whether adding dutasteride to combined androgen blockade can improve the response rate and clinical outcomes for patients with androgen receptor-positive recurrent or metastatic salivary duct carcinoma.

This study reviews the potential of dibenzo derivatives as safer cancer treatments but finds conflicting evidence about their effectiveness, possibly due to structural differences among the compounds, and reports no new results.

This report suggests that for prostate cancer patients with cardiovascular disease, prescribing the GnRH antagonist degarelix may reduce cardiac events compared to using GnRH agonists, although prescribing should consider potential cardiac risks, particularly in patients with pre-existing conditions or older age.

Hair loss is a common, often overlooked side effect of hormone treatments for breast and prostate cancer.

There is no significant link between insulin resistance and certain hair disorders like idiopathic hirsutism and androgenic alopecia.

Hair loss is a common but often unreported side effect of cancer treatments, especially for breast and prostate cancers.

Hair loss is a common side effect of hormone treatments for cancer.

This thesis investigates the underlying mechanisms and treatment options for androgenetic alopecia, highlighting the molecular roles of androgens and genetic predispositions, and evaluates current and emerging therapies, such as PROTACs and Janus Kinase inhibitors, to enhance patient management.

This study observed that both intradermotherapy with 5% minoxidil and topical minoxidil application resulted in perceived improvements in hair density and thickness among patients with androgenetic alopecia, with no significant difference between the two groups.

This review discusses current knowledge on the biological mechanisms of different types of alopecia but reports no new clinical findings; the authors highlight future research directions, especially regarding epidermal stem cells and immune pathways.

This study concluded that oral minoxidil is an effective and well-tolerated alternative to topical minoxidil for healthy patients struggling with application-related compliance issues.

This review found that while topical minoxidil is effective for treating female pattern hair loss, finasteride showed no more effectiveness than placebo, and low-level laser therapy increased hair count but with inconsistent results.

This study observed that among dermatologists in Spain, topical minoxidil and oral finasteride are the most commonly prescribed treatments for male androgenic alopecia, while oral dutasteride and oral minoxidil have seen increased use in recent years.

This review reports that the treatment of androgenetic alopecia is shifting from single therapies to personalized, multimodal approaches incorporating both traditional and emerging pharmacologics, regenerative strategies, nutraceuticals, cosmeceuticals, and device-based interventions, with combination regimens showing improved outcomes.

This study established consensus guidelines for diagnosing and managing androgenetic alopecia in Egypt, emphasizing individualized care and emerging therapies based on a survey of Egyptian dermatologists and refinement through expert review.

This chapter provides an overview of phytochemicals with properties to combat alopecia and discusses the potential of flavonoids, found in several herbs, as a safer alternative to synthetic hair loss treatments due to their long-term skin compatibility.

This article reviews the impact of aging and related urologic conditions on male fertility, highlighting the effects of various treatments on sperm parameters and recommending pre-treatment counseling for fertility preservation. It reports no new clinical results.

This review discusses the role of DHEA in intracrinology, highlighting its impact on breast and prostate cancer treatment and potential as a menopause therapy, but reports no new research findings.

This article discusses the side effects of androgen deprivation therapy for nonmetastatic prostate cancer, highlighting the need for clinical trials to systematically study these effects.

This review discusses the biochemical properties and clinical significance of 5 alpha-reductase isozymes and reports no new clinical results.